PLATINUM

📅 Upcoming

🕒 Recent(90d)

News

• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 16d ago
• Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
  The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…
  biospace · 27d ago
• Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
  Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
  stat · 2mo ago
• Merck ADC, licensed from China, hits mark in first big global trial
  The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
  biopharma_dive · 2mo ago
• AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC
  AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.
  onclive · 2mo ago
• GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
  We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
  onclive · 3mo ago
• Five Under 5: Top Oncology Videos for the Week of 5/3
  The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
  onclive · 3mo ago
• Giants of Cancer Care Announces the 14th Annual Class of Inductees
  onclive · 3mo ago
• OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
  Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
  onclive · 3mo ago
• Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
  Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.
  onclive · 3mo ago